Inovio Pharmaceuticals, Inc.

INO

$1.40

+2.57%

2026-09-04 12:22:12 EDT+$0.04

Salud

Biotecnología

NASDAQ

Negociación activa

Inovio Pharmaceuticals, Inc. es una empresa de biotecnología dedicada a la investigación, el desarrollo y la introducción en el mercado de tratamientos ...

Análisis fundamental de INO

Fortalezas clave

Innovative DNA medicine platform with potential broad applications across oncology and infectious diseases.

Strong partnership network including AstraZeneca, Regeneron, CEPI, and the Gates Foundation, providing validation and potential funding.

Factores de riesgo

No approved products and minimal revenue, relying entirely on future clinical success.

High cash burn rate with negative operating and free cash flow, leading to significant dilution risk from future capital raises.

Rentabilidad

Margen neto0.00%

Margen operativo0.00%

Valoración

PER-1.19x

Ratio corriente1.00

Eficiencia

ROE-1005.80%

ROA-136.52%

Análisis Fundamental de INO

Inovio Pharmaceuticals is a clinical-stage biotechnology company focused on developing DNA-based immunotherapies and vaccines. The company's proprietary platform combines SynCon DNA design with CELLECTRA delivery technology to generate targeted immune responses. As of the latest data, Inovio has no approved products and generates minimal revenue, reflected in a market cap of approximately $53 million and an enterprise value of $35 million. The company is in a precarious financial position: with a current ratio of 1.04 and cash per share of $0.545, it has limited liquidity to fund ongoing operations. Its cash runway is a critical concern, as the company burned through significant cash (operating cash flow TTM: -$83.6 million) and has a free cash flow yield of -158%. The balance sheet shows substantial leverage relative to equity (debt-to-equity ratio 1.43, financial leverage 8.2), although the debt is modest in absolute terms. R&D and SG&A expenses have been reduced year-over-year, but the company still reports net losses, with a net margin of -100% due to negligible revenues. The pipeline includes promising candidates for HPV-related diseases, cancer, and infectious diseases, with partnerships from AstraZeneca, CEPI, and the Gates Foundation. However, the stock has been volatile (beta 1.5) and trades near its 52-week low of $0.56, indicating low investor confidence. Analyst ratings suggest a 'hold' consensus, with significant uncertainty regarding clinical outcomes and funding. The company's future depends on successful clinical trials and potential partnerships, but the financial runway is tight, requiring additional capital raises that may dilute shareholders. Given these factors, a 'hold' rating is appropriate for long-term investors, as the risk/reward is balanced by potential upside from pipeline catalysts against near-term liquidity risks.

Fortalezas clave de INO

Innovative DNA medicine platform with potential broad applications across oncology and infectious diseases.
Strong partnership network including AstraZeneca, Regeneron, CEPI, and the Gates Foundation, providing validation and potential funding.
Deep clinical pipeline targeting unmet medical needs in HPV-related cancers and other diseases.
Proprietary CELLECTRA delivery technology enhancing the efficacy of DNA vaccines.
Reduced operating expenses over the last year, indicating improved cost management.
Cash and cash equivalents of approximately $37.5 million (based on market cap and net debt) provide some runway, though limited.

Factores de riesgo de INO

No approved products and minimal revenue, relying entirely on future clinical success.
High cash burn rate with negative operating and free cash flow, leading to significant dilution risk from future capital raises.
Limited cash runway; may need to raise capital within the next 12-18 months.
Clinical development is inherently risky, with high failure rates in Phase 3 trials.
Competition from established players in DNA vaccines and immunotherapies (e.g., Moderna, Pfizer/BioNTech).
High stock volatility and beta of 1.5, exposing investors to price swings.
Regulatory uncertainties and potential for delays or rejections in approvals.

Capitalización vs ingresos y beneficios

Beneficios

n/a

Ingresos

n/a

Capitalización bursátil

$96.04M

-1.2x

Ratio P/E

0.0x

Ratio P/S

Beneficios e ingresos

Último informen/a

Beneficio por acción (EPS)n/a

Margen bruto0.00%

Margen neto0.00%

Ratio deuda/capital1.83

Puente de rentabilidad (actual vs interanual)

Muestra cómo cambiaron el margen bruto, operativo y neto frente al año anterior.

Historial de ingresos / beneficio neto / FCF (USD B)

Señales de crecimiento de INO

Métrica	Actual	Anterior	InteranualCambio interanual: trimestre actual frente al mismo trimestre del año pasado.	TrimestralCambio trimestral: trimestre actual frente al trimestre anterior inmediato.	Señal
Ingresos	—	—	—	—	Plano
EPS diluido	—	—	—	—	Plano
Flujo de caja libre	—	—	—	—	Plano

Rentabilidad de INO

Métrica	Actual	Anterior	InteranualCambio interanual: trimestre actual frente al mismo trimestre del año pasado.	TrimestralCambio trimestral: trimestre actual frente al trimestre anterior inmediato.	Señal
Margen neto	—	0.00%	—	—	Plano
Margen operativo	—	0.00%	—	—	Plano
ROE	—	—	—	—	Plano

Salud financiera de INO

Métrica	Actual	Anterior	InteranualCambio interanual: trimestre actual frente al mismo trimestre del año pasado.	TrimestralCambio trimestral: trimestre actual frente al trimestre anterior inmediato.	Señal
Ratio corriente	—	1.000	—	—	Plano
Ratio rápido	—	1.000	—	—	Plano
Deuda / capital	—	1.831	—	—	Plano

Valoración de INO

Métrica	Actual	Anterior	InteranualCambio interanual: trimestre actual frente al mismo trimestre del año pasado.	TrimestralCambio trimestral: trimestre actual frente al trimestre anterior inmediato.	Señal
P/E	—	-3.93x	—	—	Plano
P/B	—	20.54x	—	—	Plano

Supply Chain de INO

RELATIONS

Upstream

Richter BioLogics (formerly Richter-Helm BioLogics)BUX:GDRBThermo Fisher Scientific (Patheon CDMO)NYSE:TMOKaneka EurogentecTSE:4118Resilience (National Resilience, Inc.)Inovio Device Engineering & Manufacturing Facility (San Diego, CA)Gedeon Richter PlcBUX:GDRBKaneka CorporationTSE:4118

Downstream

ApolloBio CorporationNEEQ:430187Akeso, Inc.HKEx:9926 Coherus Oncology (formerly Coherus BioSciences)NASDAQ:CHRS AstraZeneca (MedImmune)NASDAQ:AZNSpecialty Distributor (Not Yet Named Publicly)Third-Party Logistics Provider (Not Yet Named Publicly)

Proxies

Moderna, Inc.NASDAQ:MRNA BioNTech SENASDAQ:BNTX AstraZeneca PLCNASDAQ:AZN Thermo Fisher Scientific Inc.NYSE:TMO

Sobre nosotrosPolítica de privacidadTérminos de servicioAviso legalDirectorio de accionesETFÍndicesCarteras 13FPrecios objetivoHerramientas gratuitasMapa tecnológicoÚnete a nuestro Slack

Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal